Search Login Register

erlotinib (CP 358,774) Summary

Description: an inhibitor of epidermal growth factor receptor tyrosine kinase; structure in first source

Also Known As: CP 358,774; Tarceva; CP 358774; CP-358,774; CP-358774 Show All >>

Networked: 2464 relevant articles (349 outcomes, 752 trials/studies) for this Drug

Key Diseases for which erlotinib is Relevant

  1. Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) : 139 outcomes 331 studies in 1051 results
  2. Neoplasms (Cancer) : 68 outcomes 173 studies in 729 results
  3. Pancreatic Neoplasms (Pancreatic Cancer) : 38 outcomes 72 studies in 203 results
  4. Lung Neoplasms (Lung Cancer) : 33 outcomes 62 studies in 349 results
  5. Neoplasm Metastasis (Metastasis) : 20 outcomes 16 studies in 119 results
Show All >>

Drugs Related to erlotinib

  1. Epidermal Growth Factor Receptor (EGF Receptor)
  2. gefitinib (Iressa)
  3. Protein-Tyrosine Kinases (Tyrosine Kinase)
  4. gemcitabine
  5. bevacizumab
  6. erlotinib (CP 358,774)
  7. Phosphotransferases (Kinase)
  8. cetuximab (Erbitux)
  9. docetaxel (Taxotere)
  10. capecitabine (Xeloda)
Show All >>

Therapies Related to erlotinib

  1. Drug Therapy (Chemotherapy)
  2. Heterologous Transplantation (Xenotransplantation)
  3. Radiotherapy
  4. Neoadjuvant Therapy
  5. Aftercare (After-Treatment)
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.